Recombinant low virulence bovine herpesvirus-1 (BoHV-1) vaccine vectors
AssigneesThe State of Queensland Acting Through the Department of Agriculture and Fisheries, Meat & Livestock Australia Limited
InventorTimothy John Mahony
Life of this patent
Estimating the term…
Abstract
The present disclosure teaches generally in the field of vaccination and disease control in cattle and bovine animals. A recombinant bovine herpesvirus 1 (BoHV-1) vaccine vector is provided for efficient control of one or more bovine pathogens such as those associated with bovine respiratory disease complex, such as bovine viral diarrhea virus (BVDV), and which ameliorates disease conditions caused thereby. Protocols for the management of confined or herded bovine animals are also enabled herein.
Claims18
A vaccine against at least one antigen from a bovine pathogen, said vaccine comprising a bovine herpes virus-1 (BoHV-1) genome from a low virulence BoHV-1 having genetic material encoding the at least one antigen which is heterologous to BoHV-1 inserted between two converging BoHV-1 genes wherein the insertion does not substantially down-regulate expression of the BoHV-1 genes and wherein the genetic material encoding the at least one antigen is inserted between the polyadenylation signals of two converging genes at a site selected from between 16600 to 16612;
- 22449 to 22493;
- 40734 to 40768;
- 58229 to 58563;
- 67037 to 67091;
- 74994 to 75041;
- 84496 to 84528;
- 90732 to 90760;
- and 96870 to 96882 of BoHV-1 reference sequence GenBank Accession No. AJ004801.
A method of producing a vaccine against at least one antigen from a bovine pathogen, said method comprising:
- (i) incorporating a BoHV-1 genome from a low virulence BoHV-1 into a bacterial artificial chromosome (BAC) vector to form a BoHV-1 pre-vector BAC construct;
- (ii) inserting genetic material encoding the at least one antigen into the BoHV-1 pre-vector BAC construct via GET recombination to generate a recombinant BoHV-1-BAC (rBoHV-1-BAC) vector, the genetic material encoding the at least one antigen is inserted between the polyadenylation signals of two converging genes at a site selected from between 16600 to 16612;
- 2249 to 22493;
- 40734 to 40768;
- 58229 to 58563;
- 67037 to 67091;
- 74994 to 75041;
- 84496 to 84528;
- 90732 to 90760;
- and 96870 to 96882 of BoHV-1 reference sequence GenBank Accession No. AJ004801;
- (iii) transforming and amplifying the rBoHV-1-BAC vector in a bacterial host;
- and
- (iv) purifying and isolating the rBoHV-1-BAC vector from the bacterial host and formulating the vector into a vaccine composition.
Dependencies are inferred from the claim text.